유전자 도입을 위한 non-viral TcBuster mRNA Transposase & Transposon

시약 및 기기 상세

유전자 도입을 위한 non-viral TcBuster mRNA Transposase & Transposon

Maker : BIO-TECHNE

TcBuster 시스템은 바이러스를 사용하지 않고 유전자를 세포내로 전달하는 방법으로, 유전자 전달 효율이 높고 안전하여, 세포치료제 개발에 효율적으로 적용될 수 있습니다.

프린트 제품 문의

특징

TcBuster는 여러 개의 관심 유전자를 세포내로 전달하고 안정적으로 삽입할 수 있는 대용량 Transposon 시스템입니다.
바이러스 벡터에 대한 효과적인 대안인 TcBuster는 CAR T 또는 CAR NK와 같은 세포 치료제 개발 과정에서 상당한 시간과 비용 절감을 제공합니다.
바이러스 벡터 기반의 공학(예: 렌티바이러스 또는 AAV)이 세포에 DNA 화물을 전달하는 표준 방법이었지만, TcBuster 시스템은 표electroporation 방법을 사용한 비바이러스 솔루션을 제공합니다.

TcBuster 시스템이 바이러스 기반 시스템과 다른 점

세포 치료제의 시장 출시 기간 단축 및 비용 절감
증가된 cargo capacity, 높은 편집 효율, 단일 벡터에서 여러 유전자 전달
위험성이 낮은 삽입 프로파일을 통한 안정적인 DNA 발현
RUO 및 GMP 등급 재료 모두에 대한 강력하고 안정적인 공급
배치 간 변동성 감소 및 바이러스 전처리 없이 연구 단계부터 임상 및 상업 단계까지 손쉽게 확장 가능
유연하고 비독점적인 라이선스 옵션과 탄탄한 기술 및 규제 지원

TcBuster Reagent

Product	Cat. No.	Test size	Application
mRNA Transposase	TCB-001.1-100 (100 µg)	100 tests at 1 µg each	• Useful for system evaluation
	TCB-001.1-500 (500 µg)	500 tests at 1 µg each	• Useful for further development
	TCB-001.1-GMP (500 µg)	500 tests at 1 µg each	• GMP grade • Useful for pre-IND process development and ex vivo clinical applications
TcBuster-Compatible Transposons	TCBP001-100 (100 µg)	25-100 tests at 1-4 µg each	• Multicistronic CAR-containing transposon • Useful in cell therapy applications as an experimental control
	TCBP002-100 (100 µg)	25-100 tests at 1-4 µg each	• Whole plasmid insertion of eGFP with no untransposed plasmid expression • Useful in bioprocessing system evaluation as an experimental control
	Custom Transposons	-	• For process development using your own therapeutic cargo • Utilizes partnership with Aldevron™

Mechanistic Diagram of the TcBuster Non-Viral Gene Editing System

Mechanistic Diagram of the TcBuster Non-Viral Gene Editing System.

The TcBuster system components are introduced into cells via electroporation (1). The TcBuster-M transposase mRNA is then translated into the transposase enzyme (2), which binds to the inverted terminal repeats (ITRs) on the DNA transposon (3). The transposase enzyme excises the genes of interest (GOI) from the transposon (4) and inserts them into the host genome (5). The GOI mRNA is transcribed from the host genome (6), and the protein is stably expressed in the edited cells (7).

Efficient gene editing of T cells modified with different sized cargos on different electroporation platforms.

Primary T cells from 3 donors were expanded for 7 days after genetic modification in GMP Human T Cell Media (Catalog # CCM038-GMP-1L) supplemented with 5% hAB serum and 10 ng/mL each of IL-7 (Catalog # BT-007-GMP) and IL-15 (Catalog # BT-015-GMP) in a 6 well G-Rex®. (A). Representative flow plots of genetically modified T cells with a 5.1 kb insert containing a GFP sequence, introduced on the ThermoFisher Neon™, Lonza 4D- Nucleofector®, or MaxCyte®. (B).Three DNA cargos introduced on the same electroporation platforms achieve high editing efficiency in T cells (>40%). Data points represent the average of 3 donors with technical duplicates ± SD.

TcBuster edited CD19-CAR-T cells specifically kill CD19+ target cells at low E:T ratios.

T cells from 3 donors were expanded for 7 days after genetic modification in GMP Human T Cell Media (Catalog # CCM038-GMP-1L) supplemented with 5% hAB serum and 10 ng/mL each of IL-7 (Catalog # BT-007-GMP) and IL-15 (Catalog # BT-015-GMP) in a 6 well G-Rex®. (A) TcBuster efficiently integrates cargos of different sizes regardless of electroporation platform, resulting in a similar number of total modified T cells produced. (B) T cells from 3 donors modified with the 5.1 kb plasmid were cryopreserved in CS10 following 7 days of culture after electroporation. T cells were thawed and immediately added to either CD19+ or CD19- target cells at different E:T ratios and controlled target cell growth after 24 hours of co-culture.

Genetic characterization of TcBuster genetically modified primary T cells shows a favorable insertional profile and low copy number.

(A) T cells from 3 donors were collected after 9 days of culture for digital PCR analysis of the population’s average adjusted vector copy number (VCN). (B) Integration site analysis (ISA) was performed on 3 different T cell donors that were modified with a different range of plasmid sizes with TcBuster or a lentiviral vector. DNA libraries were Illumina sequenced by GeneWerk (now ProtaGene).

TcBuster edits primary T cells as efficiently or better than lentivirus.

T cells from 3 donors were expanded for 9 days in GMP Human T Cell Media, supplemented with 5% hAB serum and 10 ng/mL each of IL-7 and IL-15, in a 6 well G-Rex®. The GOI is refers to the promoter and genes integrated in the genome. Graph shows the efficiency of genetic modification for both TcBuster and lentivirus, with TcBuster showing comparable or better editing efficiency. Data points represent the average of 3 donors ± SD.

주문정보

주문정보 - Cat No, PRODUCT, SIZE, 수량 등 항목으로 구성되어있습니다.
Product	Cat.No.	Size	Maker
TcBuster-M™ Transposase mRNA	TCB-001.1-100	100 µg	BIOTECHNE
TcBuster™ Transposon CD19CAR-DHFR-eGFP	TCBP001-100	100 µg	BIOTECHNE
TcBuster™ Transposon Insert On eGFP	TCBP002-100	100 µg	BIOTECHNE
TcBuster™-M Transposase mRNA	TCB-001.1-500	500 µg	BIOTECHNE

1
Maker	BIOTECHNE
Cat.No.	TCB-001.1-100
Product	TcBuster-M™ Transposase mRNA
Size	100 µg
Qty
Data Sheet
MSDS

2
Maker	BIOTECHNE
Cat.No.	TCBP001-100
Product	TcBuster™ Transposon CD19CAR-DHFR-eGFP
Size	100 µg
Qty
Data Sheet
MSDS

3
Maker	BIOTECHNE
Cat.No.	TCBP002-100
Product	TcBuster™ Transposon Insert On eGFP
Size	100 µg
Qty
Data Sheet
MSDS

4
Maker	BIOTECHNE
Cat.No.	TCB-001.1-500
Product	TcBuster™-M Transposase mRNA
Size	500 µg
Qty
Data Sheet
MSDS

유전자 도입을 위한 non-viral TcBuster mRNA Transposase & Transposon | 고마바이오텍

유전자 도입을 위한 non-viral TcBuster mRNA Transposase & Transposon

주문정보

추천제품

관련제품

자료

웨비나/Video

제품 문의

로그인